Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target

Authors:
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP
In:
Source: Nature
Publication Date: (2023)
Issue: 11: 1592-1609
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Gene Expression
Drug Discovery
Cells used in publication:
T cell, human stim.
Species: human
Tissue Origin: blood
T cell, mouse, stim
Species: mouse
Tissue Origin: blood
Platform:
4D-Nucleofector® 96-well Systems
4D-Nucleofector® X-Unit
Experiment

Human CAR T cell generation

For aITGB2 CAR T cells, the cells were then additionally nucleofected with ribonuclease complex of ITGB2 sgRNA and Cas9 using a P3 Primary Cell 4D-Nucleofector X kit S (Lonza, V4XP-3032) and 4D-Nucleofector (Lonza) with its built-in program EO-115.

Mouse CAR T cell generation

Mouse T cells were cultured and activated for 24?h using Dynabeads Mouse T-Expander CD3/CD28 (Gibco, 11452D) and magnetically removed thereafter. T cells (2?×?10^6 ) were nucleofected with Cas9 ribonuclease complex (RNP; Lonza, V4SP-3096) using a 4D-Nucleofector 96-well unit (Lonza, AAF-1003S) and Lonza program code DN-100 with 60?pmol of Cas9 protein (QB3 MacroLab) and 120?pmol of sgRNA (UCCCUCCUCUAGAACUUCAC; Synthego) preincubated at 37?°C for 10–15 min. The culture medium was then added to the cells and incubated (37?°C, 5% CO2) for 1?h.

Generation of ITGB2-knockout cells

Knockout cell lines or primary T cells were generated using in vitro nucleofection of Cas9 ribonuclease protein complex. Briefly, 2?µl of each sgRNA (100?µM; Synthego Corporation) and recombinant Cas9 protein (40?µM; QB3 MacroLab, University of California, Berkeley) was incubated at 37?°C for 15?min to generate ribonuclease complex, which was then nucleofected using a 4D-Nucleofector (Lonza) with the built-in program DS-137 for cell lines (using Lonza V4XC-2032) and EO-115 for primary T cells (using Lonza V4XP-3032). The sgRNAs used in this study were obtained from the Brunello library (Supplementary Table 3).

Abstract

Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express cancer-specific surface protein conformations that are invisible to standard target discovery pipelines evaluating gene or protein expression, and these conformations can be identified and immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein surface capture 'structural surfaceomics'. As a proof of principle, we apply this technology to acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes and no known optimal immunotherapy target. We identify the activated conformation of integrin ß2 as a structurally defined, widely expressed AML-specific target. We develop and characterize recombinant antibodies to this protein conformation and show that chimeric antigen receptor T cells eliminate AML cells and patient-derived xenografts without notable toxicity toward normal hematopoietic cells. Our findings validate an AML conformation-specific target antigen and demonstrate a tool kit for applying these strategies more broadly.